Ixazomib
- 3 trials, none about aging, 1 with no results posted
- Humans1
- Model organisms1
Trial sponsors
1 trialPhase 240 people
1 trialPhase 220 people
1 trialPhase 1/253 people
Latest
Cell Death & Disease
The CRTC-CREB axis functions as a transcriptional sensor to protect against proteotoxic stress in Drosophila
Experiments in fliesMechanisms